Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: Results of two randomized double blind controlled multiinstitutional trials

Aman U. Buzdar, Robert Smith, Charles Vogel, Philip Bonomi, Alan M. Keller, Gregory Favis, Mary Mulagha, Judy Cooper

Research output: Contribution to journalArticle

104 Citations (Scopus)

Abstract

BACKGROUND. Breast cancer patients with prior response to endocrine therapy achieve subsequent benefit from additional endocrine therapies. The efficacy and safely of an aromatase inhibitor, fadrozole HCL, were compared with megestrol acetate in postmenopausal patients who had disease progression after receiving antiestrogen therapy for metastatic disease or as adjuvant therapy. METHODS. In 2 multiinstutional prospective trials, 683 postmenopausal patients were randomized to receive either fadrozole HCL, 1 mg twice daily, or megestrol acetate, 40 mg 4 times daily, in a double blind fashion after progression on first-line hormonal therapy. Objective response rates, time to progression, survival, and safety of the two regimens were compared. RESULTS. Results of intent-to-treat analyses are presented in this study. No significant differences were detected between the two treatment groups in time to progression, objective response rates, duration of response, and survival in either trial. There were no clinically meaningful differences between the treatment groups in the incidence and severity of adverse experiences, except that weight gain, fluid retention, and dyspnea were observed in more patients in the megestrol acetate group compared with those receiving fadrozole HCL, whereas nausea and vomiting were observed in more patients in the fadrozole HCL group compared with those receiving megestrol acetate. CONCLUSIONS. Fadrozole HCL was as efficacious as megestrol acetate in postmenopausal patients with metastatic breast carcinoma after one hormonal therapy. Adverse experiences were mild with both therapies, but megestrol acetate was associated with a higher frequency of weight gain, fluid retention, and dyspnea, whereas fadrozole HCL was associated with a higher frequency of nausea and vomiting.

Original languageEnglish
Pages (from-to)2503-2513
Number of pages11
JournalCancer
Volume77
Issue number12
DOIs
StatePublished - Jun 15 1996

Fingerprint

Fadrozole
Megestrol Acetate
Breast Neoplasms
Therapeutics
Dyspnea
Nausea
Weight Gain
Vomiting
Aromatase Inhibitors
Estrogen Receptor Modulators
Survival
Disease Progression

Keywords

  • breast carcinoma
  • fadrozole HCL
  • hormonal therapy
  • megestrol acetate
  • postmenopausal

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma : Results of two randomized double blind controlled multiinstitutional trials. / Buzdar, Aman U.; Smith, Robert; Vogel, Charles; Bonomi, Philip; Keller, Alan M.; Favis, Gregory; Mulagha, Mary; Cooper, Judy.

In: Cancer, Vol. 77, No. 12, 15.06.1996, p. 2503-2513.

Research output: Contribution to journalArticle

Buzdar, Aman U. ; Smith, Robert ; Vogel, Charles ; Bonomi, Philip ; Keller, Alan M. ; Favis, Gregory ; Mulagha, Mary ; Cooper, Judy. / Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma : Results of two randomized double blind controlled multiinstitutional trials. In: Cancer. 1996 ; Vol. 77, No. 12. pp. 2503-2513.
@article{798e203589e94c41b456c78128503916,
title = "Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: Results of two randomized double blind controlled multiinstitutional trials",
abstract = "BACKGROUND. Breast cancer patients with prior response to endocrine therapy achieve subsequent benefit from additional endocrine therapies. The efficacy and safely of an aromatase inhibitor, fadrozole HCL, were compared with megestrol acetate in postmenopausal patients who had disease progression after receiving antiestrogen therapy for metastatic disease or as adjuvant therapy. METHODS. In 2 multiinstutional prospective trials, 683 postmenopausal patients were randomized to receive either fadrozole HCL, 1 mg twice daily, or megestrol acetate, 40 mg 4 times daily, in a double blind fashion after progression on first-line hormonal therapy. Objective response rates, time to progression, survival, and safety of the two regimens were compared. RESULTS. Results of intent-to-treat analyses are presented in this study. No significant differences were detected between the two treatment groups in time to progression, objective response rates, duration of response, and survival in either trial. There were no clinically meaningful differences between the treatment groups in the incidence and severity of adverse experiences, except that weight gain, fluid retention, and dyspnea were observed in more patients in the megestrol acetate group compared with those receiving fadrozole HCL, whereas nausea and vomiting were observed in more patients in the fadrozole HCL group compared with those receiving megestrol acetate. CONCLUSIONS. Fadrozole HCL was as efficacious as megestrol acetate in postmenopausal patients with metastatic breast carcinoma after one hormonal therapy. Adverse experiences were mild with both therapies, but megestrol acetate was associated with a higher frequency of weight gain, fluid retention, and dyspnea, whereas fadrozole HCL was associated with a higher frequency of nausea and vomiting.",
keywords = "breast carcinoma, fadrozole HCL, hormonal therapy, megestrol acetate, postmenopausal",
author = "Buzdar, {Aman U.} and Robert Smith and Charles Vogel and Philip Bonomi and Keller, {Alan M.} and Gregory Favis and Mary Mulagha and Judy Cooper",
year = "1996",
month = "6",
day = "15",
doi = "10.1002/(SICI)1097-0142(19960615)77:12<2503::AID-CNCR13>3.0.CO;2-W",
language = "English",
volume = "77",
pages = "2503--2513",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "12",

}

TY - JOUR

T1 - Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma

T2 - Results of two randomized double blind controlled multiinstitutional trials

AU - Buzdar, Aman U.

AU - Smith, Robert

AU - Vogel, Charles

AU - Bonomi, Philip

AU - Keller, Alan M.

AU - Favis, Gregory

AU - Mulagha, Mary

AU - Cooper, Judy

PY - 1996/6/15

Y1 - 1996/6/15

N2 - BACKGROUND. Breast cancer patients with prior response to endocrine therapy achieve subsequent benefit from additional endocrine therapies. The efficacy and safely of an aromatase inhibitor, fadrozole HCL, were compared with megestrol acetate in postmenopausal patients who had disease progression after receiving antiestrogen therapy for metastatic disease or as adjuvant therapy. METHODS. In 2 multiinstutional prospective trials, 683 postmenopausal patients were randomized to receive either fadrozole HCL, 1 mg twice daily, or megestrol acetate, 40 mg 4 times daily, in a double blind fashion after progression on first-line hormonal therapy. Objective response rates, time to progression, survival, and safety of the two regimens were compared. RESULTS. Results of intent-to-treat analyses are presented in this study. No significant differences were detected between the two treatment groups in time to progression, objective response rates, duration of response, and survival in either trial. There were no clinically meaningful differences between the treatment groups in the incidence and severity of adverse experiences, except that weight gain, fluid retention, and dyspnea were observed in more patients in the megestrol acetate group compared with those receiving fadrozole HCL, whereas nausea and vomiting were observed in more patients in the fadrozole HCL group compared with those receiving megestrol acetate. CONCLUSIONS. Fadrozole HCL was as efficacious as megestrol acetate in postmenopausal patients with metastatic breast carcinoma after one hormonal therapy. Adverse experiences were mild with both therapies, but megestrol acetate was associated with a higher frequency of weight gain, fluid retention, and dyspnea, whereas fadrozole HCL was associated with a higher frequency of nausea and vomiting.

AB - BACKGROUND. Breast cancer patients with prior response to endocrine therapy achieve subsequent benefit from additional endocrine therapies. The efficacy and safely of an aromatase inhibitor, fadrozole HCL, were compared with megestrol acetate in postmenopausal patients who had disease progression after receiving antiestrogen therapy for metastatic disease or as adjuvant therapy. METHODS. In 2 multiinstutional prospective trials, 683 postmenopausal patients were randomized to receive either fadrozole HCL, 1 mg twice daily, or megestrol acetate, 40 mg 4 times daily, in a double blind fashion after progression on first-line hormonal therapy. Objective response rates, time to progression, survival, and safety of the two regimens were compared. RESULTS. Results of intent-to-treat analyses are presented in this study. No significant differences were detected between the two treatment groups in time to progression, objective response rates, duration of response, and survival in either trial. There were no clinically meaningful differences between the treatment groups in the incidence and severity of adverse experiences, except that weight gain, fluid retention, and dyspnea were observed in more patients in the megestrol acetate group compared with those receiving fadrozole HCL, whereas nausea and vomiting were observed in more patients in the fadrozole HCL group compared with those receiving megestrol acetate. CONCLUSIONS. Fadrozole HCL was as efficacious as megestrol acetate in postmenopausal patients with metastatic breast carcinoma after one hormonal therapy. Adverse experiences were mild with both therapies, but megestrol acetate was associated with a higher frequency of weight gain, fluid retention, and dyspnea, whereas fadrozole HCL was associated with a higher frequency of nausea and vomiting.

KW - breast carcinoma

KW - fadrozole HCL

KW - hormonal therapy

KW - megestrol acetate

KW - postmenopausal

UR - http://www.scopus.com/inward/record.url?scp=0029940269&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029940269&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0142(19960615)77:12<2503::AID-CNCR13>3.0.CO;2-W

DO - 10.1002/(SICI)1097-0142(19960615)77:12<2503::AID-CNCR13>3.0.CO;2-W

M3 - Article

C2 - 8640699

AN - SCOPUS:0029940269

VL - 77

SP - 2503

EP - 2513

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 12

ER -